REDWOOD CITY, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will participate in a fireside chat as part of the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11 at 9:30 a.m. ET. To listen to a live webcast of this event, or ...

REDWOOD CITY, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the first patient was dosed in its first-in-human clinical trial evaluating RMC-5127, a RAS(ON) G12V-selective inhibitor. The first-in-human trial, RMC-5127-001 [NCT07349537], is an open-label trial evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of RMC-5127 as both ...

Company Overview - Revolution Medicines, Inc. (NASDAQ: RVMD) is a biotechnology company focused on developing targeted therapies for cancer, known for its innovative approach to oncology, attracting interest from major pharmaceutical companies [1] Stock Performance and Analyst Ratings - Oppenheimer maintained an "Outperform" rating for RVMD, raising its price target from $75 to $150, indicating confidence in the company's future performance despite recent challenges [2][6] - RVMD's stock price recently dropped by nearly 17% after Merck withdrew from acquisition talks, with the potential deal valued between $28 billion and $32 billion [3][6] Acquisition Talks - Merck's CEO expressed interest in high-growth oncology assets, although the company typically targets acquisitions valued at $15 billion or less, which may have contributed to the stalled negotiations with RVMD [4] - AbbVie was reportedly in advanced talks to acquire Revolution Medicines earlier in January, indicating that other potential suitors may emerge, keeping the possibility of an acquisition alive [5][6] Market Capitalization and Trading Volume - Revolution Medicines' market capitalization currently stands at approximately $18.9 billion, with a trading volume of 10,173,600 shares [5]

Key Takeaways RVMD shares fell 17% after a WSJ report said MRK withdrew from buyout talks following a price impasse.The WSJ report said discussions between MRK and RVMD could resume, or another bidder could step in.RVMD is advancing daraxonrasib, with phase III PDAC data and other phase III studies expected this year.Shares of Revolution Medicines (RVMD) slipped 17% yesterday after a Wall Street Journal (WSJ) report said, quoting people familiar with the matter, that pharma bigwig Merck (MRK) was no longer ...

We recently published 10 Big Names Stumbling Hard. Revolution Medicines Inc. (NASDAQ:RVMD) was one of the worst performers on Monday. Revolution Medicines fell sharply on Monday, losing 16.91 percent to close at $97.78 apiece, as investors unloaded portfolios following news that pharmaceutical giant Merck had cancelled ongoing negotiations for its proposed acquisition of the company. According to a report by the Wall Street Journal, Merck decided to terminate talks after failing to agree on a valuation. ...

It doesn't look like the company will end up in the arms of an acquirer soon, after all.Monday was generally a good day for the stock market; nevertheless, some titles landed in negative territory. One that plunged well into the red was clinical-stage biotech Revolution Medicines (RVMD 16.76%), which took a nearly 17% hit to its share price after a media report published over the weekend. Buyout bluesOn Sunday, The Wall Street Journal wrote that Merck was no longer in discussions with Revolution regarding a ...

Welcome back to Market on Close. I'm Sam Bardis live from the floor of the New York Stock Exchange. Shares of Revolution Medicines are rallying to an all-time high earlier this month, but the stock is plummeting today.That comes after a Wall Street Journal report that is today's overlooked stock. And with more on this story, I'm joined by George Silla, senior markets correspondent. So, this has got a bit of an M&A Monday flavor to it.George, just talk us through it. >> Yeah, well, I think this is interestin ...

Revolution Medicines, Inc. (RVMD) fell 17.11 percent, or $20.14, to $97.54 in active trading, despite no company-specific news driving the move. The sharp decline appears to reflect broad selling pressure following recent gains in the stock.Shares opened significantly lower at $93.46, compared with a previous close of $117.68. The stock traded in a wide range between $92.50 and $99.51 during the session on the Nasdaq. Trading volume surged to about 7.79 million shares, well above the average volume of roug ...

Revolution Medicines, Inc. ( RVMD ) stock has had a pretty turbulent start to 2026 with speculation of a takeover from a couple of different big players. The most recent was Merck ( MRKI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciation for the rigor and challenges behin ...

U.S. stock futures were lower this morning, with the Dow futures falling around 0.1% on Monday.Shares of Revolution Medicines Inc (NASDAQ:RVMD) dipped 26.1% to $87.02 in pre-market trading.The Wall Street Journal Reported that Merck (NYSE:MRK) is no longer in talks to acquire Revolution Medicines.Revolution Medicines shares dipped 26.1% to $87.02 in pre-market trading.Here are some other stocks moving lower in pre-market trading.Erasca Inc (NASDAQ:ERAS) fell 11.5% to $8.82 in pre-market trading. Erasca anno ...